MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Avanos Medical Net Debt 2011-2026 | AVNS
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Avanos Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.7 M | 28.5 M | 84.5 M | 111 M | 26.2 M | 84 M | 120 M | -137 M | 361 M | 465 M | 449 M | 487 M | -32.2 M | 28 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 487 M | -137 M | 149 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Align Technology
ALGN
|
-925 M | $ 174.53 | -1.3 % | $ 13.1 B |  USA |
 |
Alphatec Holdings
ATEC
|
347 M | $ 11.07 | -5.06 % | $ 1.66 B | USA |
 |
Bio-Rad Laboratories
BIO
|
754 M | $ 277.5 | -1.3 % | $ 7.83 B | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | USA |
 |
Acutus Medical
AFIB
|
14.2 M | - | -26.83 % | $ 2.62 M | USA |
 |
AdaptHealth Corp.
AHCO
|
1.64 B | $ 12.22 | 0.33 % | $ 1.65 B | USA |
 |
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | USA |
 |
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 3.36 | -0.3 % | $ 126 M |  France |
 |
Cardiovascular Systems
CSII
|
-64.6 M | - | 0.15 % | $ 844 M | USA |
 |
Bruker Corporation
BRKR
|
1.91 B | $ 37.98 | -0.71 % | $ 5.66 K | USA |
 |
Cytosorbents Corporation
CTSO
|
11 M | $ 0.6 | -2.45 % | $ 37.3 M | USA |
 |
Boston Scientific Corporation
BSX
|
9.26 B | $ 61.28 | -2.05 % | $ 90.7 B | USA |
 |
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | USA |
 |
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | USA |
 |
ClearPoint Neuro
CLPT
|
3.85 M | $ 8.96 | -2.29 % | $ 254 M | USA |
 |
Electromed
ELMD
|
-10.5 M | $ 24.41 | 0.04 % | $ 206 M | USA |
 |
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | USA |
 |
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | USA |
 |
Second Sight Medical Products
EYES
|
2.62 M | - | -0.97 % | $ 54.4 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
-32.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | USA |
 |
GBS
GBS
|
-4.38 M | - | -0.57 % | $ 7.12 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M |  Canada |
 |
Globus Medical
GMED
|
-511 M | $ 91.4 | -0.61 % | $ 12.4 B | USA |
 |
Butterfly Network
BFLY
|
-65.9 M | $ 4.15 | 0.24 % | $ 878 M | USA |
 |
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | USA |
 |
BIOLASE
BIOL
|
6.1 M | - | -13.19 % | $ 166 K | USA |
 |
Delcath Systems
DCTH
|
-42.5 M | $ 9.88 | 0.3 % | $ 354 M | USA |
 |
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | USA |
 |
Inogen
INGN
|
-86.3 M | $ 6.66 | -0.15 % | $ 177 M | USA |
 |
Inspire Medical Systems
INSP
|
-433 M | $ 56.69 | 6.2 % | $ 1.66 B | USA |
 |
CONMED Corporation
CNMD
|
802 M | $ 36.93 | 0.93 % | $ 1.15 B | USA |
 |
IRIDEX Corporation
IRIX
|
-5.23 M | $ 1.04 | 0.97 % | $ 17.6 M | USA |
 |
Integer Holdings Corporation
ITGR
|
1.18 B | $ 86.67 | -0.93 % | $ 3.01 B | USA |
 |
FONAR Corporation
FONR
|
-42.8 M | $ 18.61 | -0.05 % | $ 122 M | USA |
 |
Invacare Corporation
IVC
|
299 M | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
-2.32 B | $ 79.15 | -3.13 % | $ 46.3 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
83.3 M | $ 15.94 | -0.44 % | $ 374 M | USA |
 |
Helius Medical Technologies
HSDT
|
-5.12 M | $ 1.89 | 0.53 % | $ 1.15 M | USA |
 |
LivaNova PLC
LIVN
|
-282 M | $ 63.37 | -2.0 % | $ 3.46 B |  Britain |
 |
LENSAR
LNSR
|
-10.2 M | $ 5.46 | -1.27 % | $ 65.3 M | USA |
 |
Cutera
CUTR
|
-140 M | - | -10.19 % | $ 1.99 M | USA |